Truscreen Group Ltd
ASX:TRU
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| NZ |
|
Truscreen Group Ltd
NZX:TRU
|
13.5m NZD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
189.2B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
172B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
137.5B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
135.6B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
133.3B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
58.7B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
47.6B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
51B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.8B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
36.7B USD |
Loading...
|
Market Distribution
| Min | -2 988.2% |
| 30th Percentile | -2.1% |
| Median | 4.2% |
| 70th Percentile | 9.4% |
| Max | 106.9% |
Other Profitability Ratios
Truscreen Group Ltd
Glance View
TruScreen Group Ltd. engages in the development, manufacture, and sale of cancer detection device and systems. The firm is engaged in the business of the development, manufacturing and sale of cancer detection devices and systems. Its cervical cancer screening device offers technology in cervical screening, providing detection of precancerous and cancerous cervical cells to help improve the health and well-being of women worldwide. Its real-time cervical cancer technology utilizes a digital wand, which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated algorithm framework is utilized to detect pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue. The product offers an approach to cervical screening, resolving ongoing issues with Pap smear (Pap tests), including failed samples, patient follow-up, patient discomfort and the need for supporting laboratory infrastructure.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Truscreen Group Ltd is -160.4%, which is below its 3-year median of -125.2%.
Over the last 3 years, Truscreen Group Ltd’s Net Margin has increased from -338.5% to -160.4%. During this period, it reached a low of -338.5% on Aug 30, 2022 and a high of -84.7% on Sep 30, 2024.
